Shilpa announced a $50 million expansion of its commercial peptide manufacturing facility in India, with new capacity aimed at meeting rising demand for peptide-based therapies, including GLP-1 programs. The investment includes GMP-based purification infrastructure and a large reactor footprint intended for high-volume production. The company positioned the move as supporting both high-throughput peptide synthesis and more specialized chemistry needs for next-generation oncology and rare disease peptide conjugates. For supply chain planners and peptide developers, the update indicates incremental manufacturing pull from high-growth metabolic franchises alongside continued demand for complex, potent peptide payloads.